0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
Article   |    
Association of a Serotonin Transporter Polymorphism (5-HTTLPR) With Depression, Perceived Stress, and Norepinephrine in Patients With Coronary Disease: The Heart and Soul Study
Christian Otte, M.D.; Jeanne McCaffery, Ph.D.; Sadia Ali, M.P.H.; Mary A. Whooley, M.D.
Am J Psychiatry 2007;164:1379-1384. doi:10.1176/appi.ajp.2007.06101617
Abstract

Objective: The short allele of a functional polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR) has been shown to interact with stressful life events to predict depression in otherwise healthy individuals. Whether the short allele increases risk for depression associated with the stress of a chronic illness has not been established. Method: In a cross-sectional genetic association study, the authors examined the association of 5-HTTLPR with current depression (measured by the Computerized Diagnostic Interview Schedule), perceived stress (measured by the Perceived Stress Scale), and 24-hour urinary norepinephrine excretion in 557 outpatients with chronic coronary disease. Results: Among individuals carrying an s allele, 25% (97 of 383) had current depression, compared with 17% (29 of 174) of l/l homozygotes. The unadjusted odds ratio was 1.6, with a 95% confidence interval (CI) of 1.0–2.6; the age- and gender-adjusted odds ratio was also 1.6 (95% CI=1.0–2.5). Participants carrying an s allele had a higher mean score for perceived stress than l/l homozygotes (5.4 versus 4.7) and a higher rate of moderate or high perceived stress (adjusted odds ratio=1.6, 95% CI=1.1–2.3). Mean 24-hour norepinephrine excretion was higher in s allele carriers (55.6 versus 50.2 mg/day), who were more likely to have norepinephrine values in the highest quartile (adjusted odds ratio=1.7, 95% CI=1.0–3.0). Conclusions: Among patients with chronic illness, carriers of the s allele of 5-HTTLPR are more vulnerable to depression, perceived stress, and high norepinephrine secretion. These factors may contribute to worse cardiovascular outcomes in these patients.

Abstract Teaser
Figures in this Article

The serotonin, or 5-HT (5-hydroxytryptamine), system is critically involved in the pathophysiology of mood and anxiety disorders, and drugs that target serotonergic neurotransmission are efficacious for the treatment of these disorders (1). The serotonin transporter (5-HTT) plays an important role in serotonergic neurotransmission by facilitating reuptake of 5-HT from the synaptic cleft. A repeat of 20–23 base pairs has been observed as a motif within a polymorphic region of the serotonin transporter gene, and it occurs as two prevalent alleles: one consisting of 14 repeats (the short allele variant) and another of 16 repeats (the long allele variant). This functional polymorphism in the 5- regulatory promoter region, termed 5-HTTLPR (5-HTT-gene-linked polymorphic region), alters transcription of the serotonin transporter gene (2). Specifically, the short allele of the 5-HTTLPR polymorphism is thought to reduce transcription efficiency for the gene, resulting in decreased expression of the serotonin transporter and decreased serotonin uptake in lymphoblast cell lines and blood platelets (3, 4) and decreased availability of the serotonin transporter in human imaging studies (5). The s allele appears to exert its effect independent of s allele load, i.e., in a dominant manner (6).

With remarkable consistency (exceptions are studies by Surtees et al. [7] and Gillespie et al. [8]), the s allele has been shown to interact with stressful life events to predict depression (9–16) in medically healthy subjects. In addition, 5-HTTLPR may predispose to depression in patients with severe medical illnesses that are associated with ongoing chronic stress (17). Thus, in study groups in which all patients are chronically ill, resulting in a considerable amount of stress, one might expect to find a direct effect of 5-HTTLPR on depression. Indeed, in several small studies the s allele of 5-HTTLPR has been associated with depression in patients with Parkinson’s disease (18, 19), in those with stroke (20), and in elderly patients after hip fracture (21). One Japanese study suggested that the s allele may be associated with depression in patients after acute coronary syndrome (22).

Whether these results are applicable to patients with stable coronary disease, particularly given substantial differences in allele frequency in 5-HTTLPR across populations, is unknown. We performed a cross-sectional study to determine whether the s allele of 5-HTTLPR is associated with current depression, greater perceived stress, and higher 24-hour urinary norepinephrine excretion among a group of 557 white patients with stable coronary disease who were enrolled in the Heart and Soul Study.

+

Participants

Details regarding our recruitment procedures have been published previously (23–25). In brief, we used administrative databases to identify outpatients with documented coronary disease at two Department of Veterans Affairs (VA) medical centers in California (San Francisco VA Medical Center and VA Palo Alto Health Care System), one university medical center (University of California, San Francisco), and nine public health clinics in the Community Health Network of San Francisco. Patients were eligible to participate if they had at least one of the following: a history of myocardial infarction, angiographic evidence of ≥50% stenosis in one or more coronary blood vessels, prior evidence of exercise-induced ischemia by treadmill or nuclear testing, or a history of coronary revascularization. Between September 2000 and December 2002, a total of 1,024 participants enrolled and completed a daylong study appointment at the San Francisco VA Medical Center. In genetic association studies, ethnically homogenous study groups are recommended because of the problem of population stratification (26, 27). To avoid population stratification, we chose to examine genotypes only in white patients, the largest group in the Heart and Soul Study (N=557). Our protocol was approved by the appropriate institutional review boards. After complete description of the study to the subjects, written informed consent was obtained.

+

Assessment of Depression

We assessed current (past month) depression by using the Computerized National Institute of Mental Health Diagnostic Interview Schedule (CDIS-IV) (28), a highly structured interview designed to yield psychiatric diagnoses according to DSM-IV criteria. The Diagnostic Interview Schedule (DIS) has been used extensively to study the epidemiology and treatment of depression (29). Trained research assistants (who were blinded to 5-HTTLPR status) administered the interview during the daylong baseline study appointment. Participants found to have current depression were informed that they were suffering from depression, instructed to discuss these symptoms with their primary care provider, and provided a list of local resources available for further evaluation and treatment.

+

Assessment of Perceived Stress

We measured perceived stress by using a four-item version of the Perceived Stress Scale (30), a brief and easy-to-administer measure of the degree to which situations in one’s life are appraised as stressful. The scale contains the following questions: 1) “In the last month, how often have you felt that you were unable to control the important things in your life?” 2) “In the last month, how often have you felt confident about your ability to handle your personal problems?” (reverse scored), 3) “In the last month, how often have you felt that things were going your way?” (reverse scored), and 4) “In the last month, how often have you felt difficulties were piling up so high that you could not overcome them?” The responses were scored as 0 (never), 1 (almost never), 2 (sometimes), 3 (fairly often), or 4 (very often). The total score ranges from 0 to 16, with higher scores indicating greater stress. As a dichotomous indicator of perceived stress, we chose a cut point of ≥5 to represent a median split of the study group.

+

24-Hour Urinary Norepinephrine Excretion

Details regarding the analysis of 24-hour urinary norepinephrine excretion have been described elsewhere in greater detail (23). In brief, the participants were instructed to collect all urine for 24 hours between the study appointment and the time when a researcher visited their home the next day and to keep the urine collection jugs refrigerated at all times. Research personnel arrived at the patients’ homes exactly 24 hours after the appointment to ensure accurately timed specimens and to enhance compliance with the protocol. All patients were asked whether they were able to collect all of the urine or if some fraction had been inadvertently discarded. The participants were also asked if the urine had been refrigerated throughout the 24-hour period. If the urine sample was reported to be incomplete or not refrigerated throughout the procedure, or if the volume was less than 1 liter, the subject was asked to repeat the collection, and research personnel returned 24 hours later to recollect the urine. Similarly, if the 3-liter collection jug was completely full, the subject was given two new jugs and asked to repeat the collection to ensure that no urine was inadvertently discarded.

Urinary norepinephrine was measured with gas chromatography–mass spectrometry (by personnel blinded to 5-HTTLPR status) at ARUP Laboratories (headquarters, Salt Lake City). The normal reference range is 0–100 mg/day for norepinephrine. Since the detection limit was 1.0 mg/dl for norepinephrine, levels for participants whose excretion was below this detection limit were coded as 1.0 mg/dl. The interassay coefficient of variance was <10%, and the intra-assay coefficient of variance was <8%.

To ensure adequate sampling for the norepinephrine analysis, we included only participants who had a urinary creatinine value within the normal range (0.8–2.1 g/day). For the norepinephrine analysis, we further excluded participants with medical diseases known to affect measurement of 24-hour urinary norepinephrine, including one participant with a pheochromocytoma, seven participants with incomplete urine collections, and 24 participants whose urine refrigeration was not verified.

+

Genotyping of 5-HTTLPR

5-HTTLPR genotyping was performed at the Genomics Core Facility at the University of California, San Francisco. The polymorphic promoter region (5-HTTLPR) was amplified with polymerase chain reaction (PCR) using 5′ FAM labeled forward (FAM-GGCGTTGCCGCTCTGAATG) and unlabeled reverse (GAGGGACTGAGCTGGACAACCAC) primers. Amplification was performed in a final volume of 6 ml containing 20 ng genomic DNA template, 200 mmol/liter deoxynucleotide triphosphates, 50 mM Tris, 0.15 mM (NH4)2SO4 (pH adjusted to 9.3 with NH4OH), 2.5 mM MgCl2, 0.1% Tween 20, and 0.25 U JumpStart AccuTaq LA DNA polymerase (Sigma-Aldrich, St. Louis). This was then cycled at 94°C for 1 minute and then underwent 45 cycles at 94°C for 30 seconds and 68°C for 4 minutes, with a final 30 minutes at 68°C. The PCR product was diluted (1:12), combined with 0.35 ml size standard and 9.0 ml highly deionized formamide denatured by heating at 95°C for 5 minutes and analyzed by using a 3730xl DNA analyzer with GeneMapper 4.0 analysis software (Applied Biosystems). The PCR fragment sizes for the long and short alleles are 529 base pairs (16 repeats) and 486 base pairs (14 repeats), respectively.

+

Potential Confounding or Moderating Variables

Self-reported date of birth, gender, medical history, smoking, and alcohol use were determined by questionnaire. We measured resting blood pressure by using a standard sphygmomanometer and performed a symptom-limited, graded exercise treadmill test according to a standard Bruce protocol. We defined exercise capacity as the total number of metabolic equivalents achieved at peak exercise.

+

Statistical Analysis

The goal of this investigation was to examine the association of 5-HTTLPR with depression, perceived stress, and norepinephrine secretion in patients with coronary disease. After preliminary analyses confirmed dominance of the s allele, we pursued the remaining analyses with the patients divided according to the s allele (s/s or s/l versus l/l). Differences in characteristics between participants with and without the s allele were determined by using t tests (or nonparametric equivalent) for continuous variables and chi-square tests for dichotomous variables. Analysis of covariance was used to compare mean norepinephrine excretion and mean perceived stress in participants with and without the s allele.

To determine the unadjusted and adjusted associations between s allele status and depression, perceived stress, and norepinephrine, we used logistic regression analyses with s allele status as the predictor variable. Our outcome variables were 1) presence of current depression according to the CDIS, 2) proportion with moderate or high perceived stress (score >5 on Perceived Stress Scale), and 3) proportion in the highest quartile of 24-hour urinary norepinephrine excretion. We also examined the effects of interactions between 5-HTTLPR and potential moderating variables in predicting our outcome variables. We adjusted all analyses for age and gender. The analyses were performed by using Statistical Analysis Software (version 9, SAS Institute, Cary, N.C.).

Of the 557 participants, 96 (17%) were homozygous for the s allele (s/s genotype), 287 (52%) were heterozygous (s/l genotype), and 174 (31%) were homozygous for the l allele (l/l genotype). The allele frequencies were almost identical to previously reported frequencies in white populations (4, 14). The three groups were in Hardy-Weinberg equilibrium (χ2=0.12, df=2, n.s.). No differences in age, sex, medical illness, medication use, body mass index, alcohol use, and cardiac function were observed between s allele carriers and l/l individuals. Characteristics stratified according to s allele status are shown in Table 1.

+

5-HTTLPR and Depression

Of the 557 participants, 126 (23%) were currently depressed. The proportions of participants with current depression, our primary outcome variable, were identical in individuals with the s/s genotype (24 of 96, 25%) and s/l genotype (73 of 287, 25%), confirming a dominant effect of the s allele. Therefore, we designated the individuals with the s/s and s/l genotypes as s allele carriers. Current depression was diagnosed in 25% of the individuals carrying an s allele (97 of 383), compared with 17% of the l/l carriers (29 of 174) (Figure 1); the odds ratio for depression in s allele carriers, therefore, was 1.6, as shown in Table 2. After adjustment for age and gender, this association remained but was not significant at the traditional p<0.05 cutoff point.

+

5-HTTLPR and Perceived Stress

Carriers of the s allele had a higher mean score on the Perceived Stress Scale (mean=5.4, SD=3.4) than the l/l homozygotes (mean=4.7, SD=2.9) (Figure 1). In a logistic regression analysis, s allele carriers had an increased odds of having moderate to high scores for perceived stress (Table 2). This association remained strong after adjustment for age and gender.

+

5-HTTLPR and 24-Hour Norepinephrine Excretion

Urinary 24-hour excretion of norepinephrine was higher in s allele carriers (mean=55.6 mg, SD=24.0) than in l/l homozygotes (mean=50.2, SD=23.8) (Figure 1). In a logistic regression analysis, s allele carriers had higher odds of having norepinephrine values in the highest quartile (Table 2).

+

Potential Moderating Variables

We did not find any significant effects of interactions between 5-HTTLPR and measures of cardiac disease severity, including exercise capacity (metabolic equivalents achieved), history of myocardial infarction, history of coronary artery bypass graft, or overall perceived health status in predicting depression, perceived stress, or norepinephrine excretion (all p values for interactions were >0.20).

We found that the s allele of 5-HTTLPR was associated with depression and perceived stress in patients with coronary disease. Furthermore, the s allele was associated with greater 24-hour urinary norepinephrine excretion. These results suggest that patients with the 5-HTTLPR s allele are more likely to develop depression, greater perceived stress, and high norepinephrine secretion in the presence of chronic illness.

Our results regarding the association between the s allele and depression are consistent with previous findings of an interaction of the s allele with stressful life events in predicting depression among medically healthy subjects (11–15). We have demonstrated an association between the s allele and depression in participants who were chronically stressed because of an ongoing illness. Indeed, several small studies found an association between the s allele and depression in patients with medical illness, i.e., in patients with Parkinson’s disease (18, 19), stroke (20), hip fracture (21), and coronary disease (22). Taken together, these findings suggest that chronic medical illness may be a type of stress that is more likely to lead to depression in patients with the s allele than in patients homozygous for the long allele.

The implication of our findings is that the 5-HTTLPR genotype may be an important vulnerability factor for depression and perceived stress in cardiac patients. Heart disease currently affects about 13 million Americans (31). Depression occurs in about 20% of these patients, and it is associated with an increased risk of future cardiac events and mortality (32). Studies have shown that s allele carriers do not respond as well as l/l homozygotes to treatment with selective serotonin reuptake inhibitors and show more adverse events (33), making it more difficult to treat their depression. Thus, the prognosis for coronary disease might be worse for s allele carriers than for l/l homozygotes. Indeed, one study found an association of the s allele with depressive symptoms and cardiac events in a group of Japanese patients following acute myocardial infarction (22).

However, we did not find any moderating effects of cardiac disease severity as measured by exercise capacity, history of myocardial infarction or coronary artery bypass graft, or overall perceived health on the association between 5-HTTLPR and depression, perceived stress, or norepinephrine. Participants in the Heart and Soul Study were considerably sicker than other study groups (Table 1), and small differences in disease severity may not have been sufficient to cause varying levels of stress. Grabe et al. (34) reported that mental and physical distress was modulated by s allele status and chronic disease burden in women (but not men) in a general population sample. Future studies should explore whether greater disease severity in chronic illness moderates the association between 5-HTTLPR and depression.

Currently, the mechanisms by which the s allele might increase the risk for developing depression are unknown. The s allele has been shown to be associated with lower 5-HT1A receptor binding potential, lower expression of the serotonin transporter and serotonin uptake in lymphoblasts, an enhanced amygdala response to fearful stimuli, stronger amygdala-prefrontal coupling, and uncoupling of an amygdala-cingulate circuit implicated in the extinction of negative affect in human imaging studies (6). All of these mechanisms might be relevant to the vulnerability of s allele carriers to depression.

We also found that the s allele was associated with greater 24-hour urinary norepinephrine excretion. To our knowledge, the association between 5-HTTLPR and norepinephrine has not previously been examined in humans. However, the s allele has been associated with cardiovascular reactivity to mental stress in young adult twins (35), suggesting that individuals with the s allele have a heightened propensity to show strong reactions to stress. Moreover, knocking out the serotonin transporter gene leads to enhanced stress-induced catecholamine secretion in mice (36). Since norepinephrine is a risk factor for adverse outcomes in patients with coronary disease (37–39), this might also be a mechanism by which s allele carriers have adverse cardiovascular outcomes.

Several limitations must be considered in our study. In our study group, all patients were chronically ill and thus were under a considerable amount of stress. To examine an effect of the interaction between the s allele and stress on depression, as reported in previous studies, an ideal study would also have evaluated a group of participants who were not exposed to the stress of chronic illness. Further, 5-HTTLPR was associated with neuroticism in a meta-analysis (40), and we did not measure personality dimensions. It could be argued that the association with depression is caused by an underlying association with neuroticism, rather than with the diagnostic entity of depression. We were unable to examine the association of 5-HTTLPR with depression in different ethnic groups. Further, it is possible that the CDIS resulted in some misclassification of depression, since use of a standardized instrument cannot replace the diagnosis of depression by a clinician. However, nondifferential misclassification results in weaker (not stronger) associations, and unless misclassification was associated with 5-HTTLPR, it should not have affected our results. Finally, we did not measure functional variants that have been identified within the l allele and designated as lA and lG. The effects of the lG allele on depression are thought to be similar to those of the s allele (41). Thus, genotyping for only the s and l alleles may have diluted our findings.

In summary, we found 5-HTTLPR to be modestly associated with depression, greater perceived stress, and higher 24-hour urinary norepinephrine secretion in patients with coronary disease. Individuals carrying an s allele may be at greater risk for depression in the presence of chronic illness.

+Received Oct. 3, 2006; revision received Jan. 1, 2007; accepted Feb. 1, 2007 (doi: 10.1176/appi.ajp.2007.06101617). From the Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf; the Weight Control and Diabetes Research Center, Brown Medical School and Miriam Hospital, Providence, R.I.; the Division of General Internal Medicine, Department of Medicine, Department of Veterans Affairs Medical Center, San Francisco; and the Departments of Medicine and of Epidemiology and Biostatistics, University of California, San Francisco. Address correspondence and reprint requests to Dr. Otte, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; otte@uke.uni-hamburg.de (e-mail).

+The authors report no competing interests.

+This work was supported by grants from the Department of Veterans Affairs (Epidemiology Merit Review Program), the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program), and the Ischemia Research and Education Foundation. Dr. Otte was supported by a Young Investigator Award from the National Alliance for Research on Schizophrenia and Depression and by a Research Career Development Award from the University Medical Center Hamburg-Eppendorf (F-144-1). None of these funding sources had any role in the collection of data, interpretation of results, or preparation of this manuscript.

1.Nemeroff CB, Owens MJ: Treatment of mood disorders. Nat Neurosci 2002; 5(Nov suppl):1068–1070
 
2.Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66:2621–2624
 
3.Greenberg B, Tolliver T, Huang S, Li Q, Bengel D, Murphy D: Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet B Neuropsychiatr Genet 1999; 88:83–87
 
4.Lesch K-P, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274:1527–1531
 
5.Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR: A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47:643–649
 
6.Brown SM, Hariri A: Neuroimaging studies of serotonin gene polymorphisms: exploring the interplay of genes, brain, and behavior. Cogn Affect Behav Neurosci 2006; 6:44–52
 
7.Surtees P, Wainwright N, Willis-Owen S, Luben R, Day N, Flint J: Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder. Biol Psychiatry 2006; 59:224–229
 
8.Gillespie N, Whitfield J, Williams B, Heath A, Martin N: The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol Med 2005; 35:101–111
 
9.Jacobs N, Kenis G, Peeters F, Derom C, Vlietinck R, van Os J: Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression. Arch Gen Psychiatry 2006; 63:989–996
 
10.Eley T, Sugden K, Corsico A, Gregory A, Sham P, McGuffin P, Plomin R, Craig I: Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 2004; 9:908–915
 
11.Wilhelm KAY, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, Blair IP, Parker G, Schofield PR: Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry 2006; 188:210–215
 
12.Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, Heidmann V, Kovalenko S, Eckermann A, Kölsch H, Metten M, Zobel A, Becker T, Nöthen MM, Propping P, Heun R, Maier W, Rietschel M: The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry 2005; 57:247–251
 
13.Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B: The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 2005; 62:529–535
 
14.Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386–389
 
15.Kaufman J, Yang B-Z, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, Gelernter J: Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci USA 2004; 101:17316–17321
 
16.Zalsman G, Huang Y, Oquendo MA, Burke AK, Hu X, Brent DA, Ellis SP, Goldman D, Mann JJ: Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 2006; 163:1588–1593
 
17.McCaffery JM, Frasure-Smith N, Dube M-P, Theroux P, Rouleau GA, Duan Q, Lesperance F: Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med 2006; 68:187–200
 
18.Mössner R, Henneberg A, Schmitt A, Syagailo Y, Grassle M, Hennig T, Simantov R, Gerlach M, Riederer P, Lesch K: Allelic variation of serotonin transporter expression is associated with depression in Parkinson’s disease. Mol Psychiatry 2001; 6:350–352
 
19.Menza M, Palermo B, DiPaola R, Sage J, Ricketts M: Depression and anxiety in Parkinson’s disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 1999; 12:49–52
 
20.Ramasubbu R, Tobias R, Buchan AM, Bech-Hansen NT: Serotonin transporter gene promoter region polymorphism associated with poststroke major depression. J Neuropsychiatry Clin Neurosci 2006; 18:96–99
 
21.Lenze EJ, Munin MC, Ferrell RE, Pollock BG, Skidmore E, Lotrich F, Rogers JC, Quear T, Houck P, Reynolds CF III: Association of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) genotype with depression in elderly persons after hip fracture. Am J Geriatr Psychiatry 2005; 13:428–432
 
22.Nakatani D, Sato H, Sakata Y, Shiotani I, Kinjo K, Mizuno H, Shimizu M, Ito H, Koretsune Y, Hirayama A, Hori M, Osaka Acute Coronary Insufficiency Study Group: Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am Heart J 2005; 150:652–658
 
23.Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley MA: Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 2005; 162:2139–2145
 
24.Otte C, Marmar CR, Pipkin SS, Moos R, Browner WS, Whooley MA: Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study. Biol Psychiatry 2004; 56:241–247
 
25.Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA: Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290:215–221
 
26.Hattersley A, McCarthy M: What makes a good genetic association study? Lancet 2005; 366:1315–1323
 
27.Schulze T, Mahon FM: Genetic association mapping at the crossroads: which test and why? overview and practical guidelines. Am J Med Genet B Neuropsychiatr Genet 2002; 114:1–11
 
28.Robins LN, Helzer JE, Croughan J, Ratcliff KS: National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristics, and validity. Arch Gen Psychiatry 1981; 38:381–389
 
29.Wells KB, Hays RD, Burnam MA, Rogers W, Greenfield S, Ware JE Jr: Detection of depressive disorder for patients receiving prepaid or fee-for-service care: results from the Medical Outcomes Study. JAMA 1989; 262:3298–3302
 
30.Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Soc Behav 1983; 24: 385–396
 
31.American Heart Association: Heart Disease and Stroke Statistics—2003 Update. Dallas, AHA, 2002
 
32.Whooley MA: Depression and cardiovascular disease: healing the broken-hearted. JAMA 2006; 295:2874–2881
 
33.Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF: Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61:1163–1169
 
34.Grabe HJ, Lange M, Wolff B, Völzke H, Lucht M, Freyberger HJ, John U, Cascorbi I: Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Mol Psychiatry 2005; 10:220–224
 
35.McCaffery JM, Bleil M, Pogue-Geile MF, Ferrell RE, Manuck SB: Allelic variation in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cardiovascular reactivity in young adult male and female twins of European-American descent. Psychosom Med 2003; 65:721–728
 
36.Tjurmina OA, Armando I, Saavedra JM, Goldstein DS, Murphy DL: Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 2002; 143:4520–4526
 
37.Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T, Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819–823
 
38.Anand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, for the Val-HeFT investigators: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation 2003; 107:1278–1283
 
39.Meredith IT, Broughton A, Jennings GL, Esler MD: Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991; 325:618–624
 
40.Sen S, Burmeister M, Ghosh D: Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 2004; 127:85–89
 
41.Nakamura M, Ueno S, Sano A, Tanabe H: The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5:32–38
 
 
Figure 1. Depression, Stress, and Norepinephrine Excretion in Patients With Coronary Disease, by Genotype for the 5-HTTLPR Serotonin Transporter Polymorphism

aDepression was assessed for the past month. Significant difference between groups (χ2=4.3, df=1, p=0.04).

bSignificant difference between groups (ANCOVA: F=4.7, df=1, 556, p=0.02).

cSignificant difference between groups (ANCOVA: F=3.6, df=1, 556, p=0.04).

Figure 1. Depression, Stress, and Norepinephrine Excretion in Patients With Coronary Disease, by Genotype for the 5-HTTLPR Serotonin Transporter Polymorphism

aDepression was assessed for the past month. Significant difference between groups (χ2=4.3, df=1, p=0.04).

bSignificant difference between groups (ANCOVA: F=4.7, df=1, 556, p=0.02).

cSignificant difference between groups (ANCOVA: F=3.6, df=1, 556, p=0.04).

+

References

1.Nemeroff CB, Owens MJ: Treatment of mood disorders. Nat Neurosci 2002; 5(Nov suppl):1068–1070
 
2.Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66:2621–2624
 
3.Greenberg B, Tolliver T, Huang S, Li Q, Bengel D, Murphy D: Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet B Neuropsychiatr Genet 1999; 88:83–87
 
4.Lesch K-P, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274:1527–1531
 
5.Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR: A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47:643–649
 
6.Brown SM, Hariri A: Neuroimaging studies of serotonin gene polymorphisms: exploring the interplay of genes, brain, and behavior. Cogn Affect Behav Neurosci 2006; 6:44–52
 
7.Surtees P, Wainwright N, Willis-Owen S, Luben R, Day N, Flint J: Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder. Biol Psychiatry 2006; 59:224–229
 
8.Gillespie N, Whitfield J, Williams B, Heath A, Martin N: The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol Med 2005; 35:101–111
 
9.Jacobs N, Kenis G, Peeters F, Derom C, Vlietinck R, van Os J: Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression. Arch Gen Psychiatry 2006; 63:989–996
 
10.Eley T, Sugden K, Corsico A, Gregory A, Sham P, McGuffin P, Plomin R, Craig I: Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 2004; 9:908–915
 
11.Wilhelm KAY, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, Blair IP, Parker G, Schofield PR: Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry 2006; 188:210–215
 
12.Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, Heidmann V, Kovalenko S, Eckermann A, Kölsch H, Metten M, Zobel A, Becker T, Nöthen MM, Propping P, Heun R, Maier W, Rietschel M: The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry 2005; 57:247–251
 
13.Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B: The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 2005; 62:529–535
 
14.Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386–389
 
15.Kaufman J, Yang B-Z, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, Gelernter J: Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci USA 2004; 101:17316–17321
 
16.Zalsman G, Huang Y, Oquendo MA, Burke AK, Hu X, Brent DA, Ellis SP, Goldman D, Mann JJ: Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 2006; 163:1588–1593
 
17.McCaffery JM, Frasure-Smith N, Dube M-P, Theroux P, Rouleau GA, Duan Q, Lesperance F: Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med 2006; 68:187–200
 
18.Mössner R, Henneberg A, Schmitt A, Syagailo Y, Grassle M, Hennig T, Simantov R, Gerlach M, Riederer P, Lesch K: Allelic variation of serotonin transporter expression is associated with depression in Parkinson’s disease. Mol Psychiatry 2001; 6:350–352
 
19.Menza M, Palermo B, DiPaola R, Sage J, Ricketts M: Depression and anxiety in Parkinson’s disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 1999; 12:49–52
 
20.Ramasubbu R, Tobias R, Buchan AM, Bech-Hansen NT: Serotonin transporter gene promoter region polymorphism associated with poststroke major depression. J Neuropsychiatry Clin Neurosci 2006; 18:96–99
 
21.Lenze EJ, Munin MC, Ferrell RE, Pollock BG, Skidmore E, Lotrich F, Rogers JC, Quear T, Houck P, Reynolds CF III: Association of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) genotype with depression in elderly persons after hip fracture. Am J Geriatr Psychiatry 2005; 13:428–432
 
22.Nakatani D, Sato H, Sakata Y, Shiotani I, Kinjo K, Mizuno H, Shimizu M, Ito H, Koretsune Y, Hirayama A, Hori M, Osaka Acute Coronary Insufficiency Study Group: Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am Heart J 2005; 150:652–658
 
23.Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley MA: Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 2005; 162:2139–2145
 
24.Otte C, Marmar CR, Pipkin SS, Moos R, Browner WS, Whooley MA: Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study. Biol Psychiatry 2004; 56:241–247
 
25.Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA: Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290:215–221
 
26.Hattersley A, McCarthy M: What makes a good genetic association study? Lancet 2005; 366:1315–1323
 
27.Schulze T, Mahon FM: Genetic association mapping at the crossroads: which test and why? overview and practical guidelines. Am J Med Genet B Neuropsychiatr Genet 2002; 114:1–11
 
28.Robins LN, Helzer JE, Croughan J, Ratcliff KS: National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristics, and validity. Arch Gen Psychiatry 1981; 38:381–389
 
29.Wells KB, Hays RD, Burnam MA, Rogers W, Greenfield S, Ware JE Jr: Detection of depressive disorder for patients receiving prepaid or fee-for-service care: results from the Medical Outcomes Study. JAMA 1989; 262:3298–3302
 
30.Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Soc Behav 1983; 24: 385–396
 
31.American Heart Association: Heart Disease and Stroke Statistics—2003 Update. Dallas, AHA, 2002
 
32.Whooley MA: Depression and cardiovascular disease: healing the broken-hearted. JAMA 2006; 295:2874–2881
 
33.Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF: Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61:1163–1169
 
34.Grabe HJ, Lange M, Wolff B, Völzke H, Lucht M, Freyberger HJ, John U, Cascorbi I: Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Mol Psychiatry 2005; 10:220–224
 
35.McCaffery JM, Bleil M, Pogue-Geile MF, Ferrell RE, Manuck SB: Allelic variation in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cardiovascular reactivity in young adult male and female twins of European-American descent. Psychosom Med 2003; 65:721–728
 
36.Tjurmina OA, Armando I, Saavedra JM, Goldstein DS, Murphy DL: Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 2002; 143:4520–4526
 
37.Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T, Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819–823
 
38.Anand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, for the Val-HeFT investigators: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation 2003; 107:1278–1283
 
39.Meredith IT, Broughton A, Jennings GL, Esler MD: Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991; 325:618–624
 
40.Sen S, Burmeister M, Ghosh D: Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 2004; 127:85–89
 
41.Nakamura M, Ueno S, Sano A, Tanabe H: The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5:32–38
 
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Web of Science® Times Cited: 70

Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 15.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 15.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 10.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 47.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 10.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles